Evaluating the potential clinical practice impact of the <scp>PromarkerD</scp> blood test in people with type 2 diabetes in Australia
Predictive PromarkerD risk scores could improve CKD prevention in T2D by enabling early intervention and guided treatment strategies, with the potential to improve patient outcomes.
Authors
- I.A. Joubert (ORCID: https://orcid.org/0000-0002-2670-0799)
- Merlin C. Thomas (ORCID: https://orcid.org/0000-0003-0694-8743)
- Lianzhi Chen (ORCID: https://orcid.org/0000-0003-4372-3068)
- Kirsten E. Peters (ORCID: https://orcid.org/0000-0003-1406-8797)
- Li Ying Kam
- Pearl Lin Tan
Institutions
- Abterra Biosciences (United States) (US)
- Monash University (AU)
Publication Details
- Journal
- Internal Medicine Journal
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1111/imj.70294
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00